# A Study to Evaluate the Efficacy, Safety and Immunogenicity of Leucostim® Versus Neupogen® in Breast Cancer Patients

> **NCT03343145** · PHASE3 · COMPLETED · sponsor: **Dong-A ST Co., Ltd.** · enrollment: 143 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **BIOLOGICAL:** Leucostim 5µg/kg/day
- **BIOLOGICAL:** Neupogen 5µg/kg/day

## Key facts

- **NCT ID:** NCT03343145
- **Lead sponsor:** Dong-A ST Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-12
- **Primary completion:** 2019-01-28
- **Final completion:** 2019-07-29
- **Target enrollment:** 143 (ACTUAL)
- **Last updated:** 2020-12-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03343145

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03343145, "A Study to Evaluate the Efficacy, Safety and Immunogenicity of Leucostim® Versus Neupogen® in Breast Cancer Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03343145. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*